Trial: Abiraterone acetate responses even after initial hormone therapy failure

(University of Colorado Anschutz Medical Campus) Results of a 40-person clinical trial published in JAMA Oncology show that 13 percent of prostate cancer patients deemed 'hormone refractory' did, in fact, have strong responses to treatment with the next-generation hormonal drug abiraterone acetate.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news